Nihon Kohden Corporation · TSE:6849
Nihon Kohden — H1 FY2026 Earnings Presentation
37 slides from Nihon Kohden's earnings presentation, Nov 10, 2026
Slide 1: Consolidated Financial Highlights for the First Half of FY2026
Consolidated Financial Highlights for the First Half of FY2026 ending March 31, 2027 1. Consolidated Financial Results for FY2026 1H 2. Forecast for FY2026 3. Business Strategy (Securities Code: 6849) November 11, 2026
Slide 2: Consolidated Financial Results for the First Half of FY2026
Consolidated Financial Results 1 for the First Half of FY2026 © Copyright NIHON KOHDEN CORPORATION All Rights Reserved 1
Slide 3: 1.1) Executive Summary
1.1) Executive Summary In FY26 2Q, overseas sales increased significantly, mainly in North America, and operating income increased excluding the impact of Abbott products Overall sales YoY -4.4%; On a local currency basis excl. Abbott products +2% FY2026 1H Operating income -40.5% Sales: Domestic s
Slide 4: 1.2) Executive Summary
1.2) Executive Summary Aiming for operating income improvement in FY26 2H by focusing on selling in-house products FY2026 Forecast Sales: Revised downward by ¥4 bn to ¥228.5 bn Domestic sales are revised downward by ¥7.5 bn. +2% excl. Abbott products. Reflecting continued cautious capital expenditu
Slide 5: Consolidated Operating Results for FY2026 1H/2Q
2) Consolidated Operating Results for FY2026 1H/2Q (Amounts of less than ¥1 million are rounded down) FY2025 FY2026 YoY FY2025 FY2026 YoY 1H 1H (%) 2Q 2Q (%) +2% on a local currency basis Net sales 108,120 103,369 - 4.4 excl. Abbott products 58,100 55,963 - 3.7 +3% Domestic sales 66,880 55,733 - 16.
Slide 6: Breakdown of Operating Income for FY2026 1H
3.1) Breakdown of Operating Income for FY2026 1H (Amounts of less than ¥1 million are rounded down) 8,000 Decrease income -967 Increase in gross profit from 7,000 actual increase in sales FY25 +1,276 6,000 1H 6,741 Impact of selling prices and cost Increase 5,000 Currency Decrease in Adjusted -2,054
Slide 7: Breakdown of Operating Income for FY2026 2Q
3.2) Breakdown of Operating Income for FY2026 2Q (Amounts of less than ¥1 million are rounded down) 6,000 Increase income +586 5,000 FY25 2Q Impact of FY26 5,341 Decrease in Adjusted Increase in selling prices 2Q 4,000 gross profit of FY25 gross profit from and cost Increase Currency 4,996 Abbott pr
Slide 8: Domestic Sales (excl. Abbott products)
4) Domestic Sales (excl. Abbott products) Sales of in-house/ Sales by product category (Sales, millions of yen) Sales by market third-party products Domestic sales FY2025 FY2026 YoY Universities Public hospitals In-house products Third-party products Private hospitals Clinics excl. Abbott products 1
Slide 9: (Ref.) Domestic Sales (incl. Abbott products)
(Ref.) Domestic Sales (incl. Abbott products) Sales by market Sales of in-house/ Sales by product category (Sales, millions of yen) third-party products Domestic sales FY2025 FY2026 YoY Universities Public hospitals In-house products Third-party products incl. Abbott products 1H 1H (%) (¥100 million
Slide 10: Overseas Sales
5) Overseas Sales FY2025 1H FY2026 1H Overseas sales: YoY +16% Overseas sales ratio (on a local currency basis: +6%) 38.1% 46.1% Sales by region Local currency Sales by product category (Sales, millions of yen) (¥100 million) YoY basis 500 476 FY2025 FY2026 YoY Local currency Asia & 1H 1H (%) 412 10
Slide 11: Sales in North America
5.1) Sales in North America Double-digit growth on yen basis / local currency basis in FY26 1H, driven by installation of large orders for Patient Monitors in FY26 2Q Strong growth of patient monitors and ventilators, double-digit growth of neurology products, decline in sales of AEDs YoY +21% (
Slide 12: Sales in Latin America
5.2) Sales in Latin America Double-digit growth in FY26 1H, thanks to strong growth in Brazil and Mexico in FY26 2Q YoY +30% (Local currency basis +17%) [ Product Category ] * YoY on a local currency basis (¥100 million) 30 Physiological Measuring Equipment: high-single-digit growth 26 Double-di
Slide 13: Sales in Europe
5.3) Sales in Europe Increased significantly thanks to large orders in Greece, Poland, and the U.K., as well as strong growth in the Netherlands and Germany YoY +21% (Local currency basis +10%) [ Product Category ] * YoY on a local currency basis (¥100 million) 80 75 Physiological Measuring Equi
Slide 14: Sales in Asia & Other
5.4) Sales in Asia & Other Decreased in FY26 1H, mainly due to lower sales in the Middle East & Africa in FY26 2Q compared to strong growth thanks to large orders in FY25 2Q YoY -1% (Local currency basis -8%) [ Product Category ] * YoY on a local currency basis (¥100 million) 120 Physiological M
Slide 15: (Ref.) Sales / Gross Margin by Product Category
(Ref.) Sales / Gross Margin by Product Category (Sales, millions of yen) Sales composition FY2025 FY2026 YoY excl. Abbott products by product category 1H 1H (%) (%) (FY2025 1H FY2026 1H) Physiological Measuring 26,053 20,021 - 23.2 6.3 Equipment (45%) (53%) 37,559 40,680 8.3 ― Patient Monitors (65
Slide 16: (Ref.) Breakdown of Sales by Product Category
(Ref.) Breakdown of Sales by Product Category FY2025 FY2026 YoY FY2025 FY2026 YoY 1H 1H (%) 1H (Sales, 1H (%) millions of yen) Neurology Products 7,780 8,091 4.0 Defibrillators 4,066 4,481 10.2 (for Hospital and Ambulance) ECGs (Electrocardiographs) 3,002 3,058 1.9 AEDs 12,158 12,518 3.0 (Automated
Slide 17: Financial Position
6) Financial Position (Amounts of less than ¥1 million are rounded down) FY2026 FY2026 FY2025 Change FY2025 Change 1H 1H Current assets 177,808 170,710 - 7,098 Current liabilities 49,428 43,138 - 6,290 Inventories 55,992 53,459 - 2,533 Interest-bearing debt 50 50 ― Property, plant & equipment 32,250
Slide 18: Cash Flows
7) Cash Flows (Amounts of less than ¥1 million are rounded down) (Billions of yen) FY2025 FY2026 FY25 1H FY26 1H Change Change 1H 1H Income before income taxes Ⅰ. Net cash flows from 6.7 3.0 -3.6 11,740 18,992 7,252 Decrease (increase) in accounts receivable operating activities 13.4 17.8 +4.4 Ⅱ. Ne
Slide 19: Capital Investment and R&D Expenses
8) Capital Investment and R&D Expenses (Amounts of less than ¥1 million are rounded down) FY2025 FY2026 FY2025 FY2026 Change 1H 1H Actual Original forecast Revised forecast announced May 14 announced Nov 10 Capital investment 1,721 1,661 - 59 7,807 6,000 6,000 Depreciation 2,164 2,649 484 4,757 6,00
Slide 20: Forecast for FY2026
2 Forecast for FY2026 © Copyright NIHON KOHDEN CORPORATION All Rights Reserved 19
Slide 21: Business Environment
1) Business Environment The global economic outlook is expected to remain uncertain due to geopolitical risks and policy trends in the U.S., as well as higher oil prices and difficulties in procuring parts and components Japan International Securing medical staff and promoting reforms in their work
Slide 22: Forecast for FY2026
2) Forecast for FY2026 FY2025 FY2026 YoY (Amounts of less than ¥1 million are rounded down) Actual Original forecast Revised forecast (%) +4% on a comparable basis announced May 14 announced Nov 10 excl. currency effect, Ad-Tech’s fiscal term Net sales 235,099 232,500 228,500 - 2.8 change, and Abbot
Slide 23: Reasons for Revisions
3) Reasons for Revisions Domestic • +2% excl. Abbott products sales • Reflecting continued cautious capital expenditure on medical equipment in 1H [ down and delays in supply of third-party products ¥7.5 bn ] • AEDs: expected to exceed original forecast due to recovery from 2Q Net sales [ down ¥4.0
Slide 24: Analysis of FY2026 Sales Forecast
3.1) Analysis of FY2026 Sales Forecast Original forecast Increase (¥100 million) Abbott Increase in products sales in Increase in in overseas Currency -213 Japanese AED sales sales effect hospital and in Japan +85 -1 FY25 ¥23.6bn FY26 ¥2.3bn clinic market +7 2,350 +97 2,325 +7 -84 +2 North America
Slide 25: Analysis of FY2026 Operating Income Forecast
3.2) Analysis of FY2026 Operating Income Forecast Original forecast (¥100 million) Impact of increase/decrease Increase in in sales other SG&A Increase in Impact of such as Depreciation Currency +2 selling prices Personnel FY26 and R&D effect 235 FY25 and cost expenses expenses -1 187 +78 -15 -16 Be
Slide 26: Consolidated Forecast for FY2026 by Product Category / Effect of Exchange Rates
(Ref.) Consolidated Forecast for FY2026 by Product Category / Effect of Exchange Rates FY2025 FY2026 YoY (Amounts of less than ¥1 million are rounded down) Original forecast Revised forecast Composition Actual announced May 14 announced Nov 10 ratio (%) (%) Physiological Measuring 53,636 41,200 43,4
Slide 27: Business Strategy
3 Business Strategy © Copyright NIHON KOHDEN CORPORATION All Rights Reserved 26
Slide 28: Long-term Vision and Three-year Business Plan
Long-term Vision and Three-year Business Plan We contribute to the world by fighting disease and improving health with advanced technology, and create a fulfilling life for our employees. Create a better future for people and healthcare Management by solving global medical issues Philosophy Targets
Slide 29: Three Transformation for BEACON 2030
Three Transformation for BEACON 2030 1 • Promote overseas business strategies emphasizing high growth and improved profitability • Develop sophisticated value propositions and cultivate new businesses areas in domestic business • Create new business models by utilizing our global business foundation
Slide 30: 3 Indicators and 6 Key Measures
3 Indicators and 6 Key Measures Implement the reform of the profit structure and make investments in growth areas, and accelerate our transformation into a global MedTech company 1) Growth 2) Profitability 3) Capital efficiency Sales CAGR Operating income margin ROE FY2023 - FY2026 in FY2026 in FY20
Slide 31: Focus on stable growth in Japan
Growth Focus on stable growth in Japan Market Phase II FY2016 - FY2025 Locally 10-year sales In-house products +4.1% Purchased growth rate sales target Medical devices +2.5% purchased CAGR products products Approx.1~2% CAGR 3% Consumables & services +5.6% +1.8% +1.6% (Ratio of consumables and servic
Slide 32: Focus on higher growth in North America
Growth Focus on higher growth in North America Market Phase II FY2016 - FY2025 Physiological Treatment growth rate sales target 10-year sales Patient Monitors Measuring CAGR Equipment mid-single-digit CAGR 11% +10% Equipment* +13% +20% +14% * Consolidated Ad-Tech in FY2025 Ventilators Patient monito
Slide 33: Implement the reform of the profit structure
Profitability Implement the reform of the profit structure OPM Improvement: 80 bps in FY2024 300 bps (YoY +220 bps) in FY2025 FY2026 Target improvement Expected 450 bps (YoY +150 bps) in FY2026 5%pt Continuing to implement measures in three key areas to improve profitability Area Theme Details o
Slide 34: Introduce Nihon Kohden's own ROIC formula
Capital efficiency Introduce Nihon Kohden’s own ROIC formula Visualizing NK’s own ROIC in each R&D, production, sales, and administration division. Providing feedback for improvement in profitability and efficiency Promoting monitoring of ROIC and CCC at subsidiaries in North America Cost of c
Slide 35: Target and Forecast for the Last Year of the Three-year Plan
Target and Forecast for the Last Year of FY2023 Actual FY2026 Target FY2026 Forecast CAGR Net sales ¥221.9 bn ¥256.0 bn ¥228.5 bn +1% Domestic sales ¥142.3 bn ¥157.0 bn ¥126.0 bn -4% Overseas sales ¥79.6 bn (35.9%) ¥99.0 bn (38.7%) ¥102.5 bn (44.9%) +9% (Overseas sales ratio) Consumables and service
Slide 36: Capital Policy
Capital Policy Make investments for future business expansion and enhance shareholder returns as well as securing a sound financial foundation. • R&D investments in patient monitors, ventilators, and Digital Health Solutions 1) Investment • Capital investments for establishing a new plant in Tsuruga
Slide 37: Disclaimer
Disclaimer: The contents of this document are based on the Company’s best judgments at the time it was prepared and do not constitute a guarantee or promise that the Company will achieve its numerical targets or implement the measures described therein. Information on products (including products un